Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 6:45 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–95 of 95 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: CTC Clear all

Conditions: Metastatic Breast Cancer
Interventions: Blood collection; Other
Lead sponsor: Janssen Diagnostics, LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 18
States / cities: Phoenix, Arizona • Fort Myers, Florida • St. Petersburg, Florida + 14 more

Conditions: Metastatic Cancer, Breast Cancer, Lobular Breast Carcinoma
Interventions: 18F-fluorofuranylnorprogesterone, Liquid Biopsy, Positron Emission Tomography/Computed Tomography; Drug · Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Pancreatic Cancer, Pancreatic Adenocarcinoma
Interventions: CTC isolocation and analysis; Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 4
States / cities: Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 1 more

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Defense and Veterans Center for Integrative Pain Management; Other
Eligibility: 18 Years to 85 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Primary Lung Cancer
Interventions: Not listed
Lead sponsor: Epic Sciences; Industry
Eligibility: 19 Years and older
Enrollment: 232 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 3
States / cities: La Jolla, California • New Haven, Connecticut • Billings, Montana

Conditions: Melanoma
Interventions: Blood Draw; Other
Lead sponsor: Wolfram Samlowski; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Small Cell Lung Cancer
Interventions: Not listed
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 2
States / cities: Kansas City, Kansas • Omaha, Nebraska

Conditions: Colorectal Cancer
Interventions: Not listed
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Colorectal Polyps
Interventions: CTC surveillance; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 50 Years and older
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2016
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Cervical Cancer, HPV
Interventions: Blood Assayed for CTCs; Diagnostic Test
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Glioblastoma, Glioblastoma Multiforme
Interventions: Carvedilol; Drug
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Prostate Cancer
Interventions: CTC biomarker expression prevalence; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Melanoma
Interventions: Ipilimumab, Stereotactic Ablative Radiosurgery (SART); Drug · Radiation
Lead sponsor: Wolfram Samlowski; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: COVID-19
Interventions: CytoSorb 300 mL device; Device
Lead sponsor: CytoSorbents, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 7
States / cities: Aurora, Colorado • Chicago, Illinois • Indianapolis, Indiana + 4 more

Conditions: Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions: ONCObind (Onco-Seraph) 100 Filter; Device
Lead sponsor: ExThera Medical Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Breast Cancer, Metastatic Breast Cancer
Interventions: trastuzumab, vinorelbine; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Colorectal Cancer
Interventions: CT Colonography; Procedure
Lead sponsor: American College of Radiology Imaging Network; Network
Eligibility: 50 Years and older
Enrollment: 2,600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 14
States / cities: Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 11 more

Conditions: Colonic Polyps, Colonic Neoplasms
Interventions: CT colonography and optical colonoscopy; Device
Lead sponsor: Japanese CT Colonography Society; Other
Eligibility: 20 Years and older
Enrollment: 1,257 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Metastatic Breast Cancer (MBC)
Interventions: Not listed
Lead sponsor: Menarini Silicon Biosystems, INC; Industry
Eligibility: 18 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Renal Cell Carcinoma
Interventions: Not listed
Lead sponsor: University of Kansas; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Triple Negative Breast Cancer, Natural Killer Cells, BRCA Mutation
Interventions: LiquidBiopsy®, NK VueTM; Device
Lead sponsor: Cynvenio Biosystems; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2015
U.S. locations: 1
States / cities: Westlake Village, California

Conditions: Metastatic Breast Cancer
Interventions: Observational; Other
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 99 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Prostate Cancer, Prostate Adenocarcinoma, Prostate Cancer Metastatic, Castration-resistant Prostate Cancer
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: New York, New York • Durham, North Carolina • Madison, Wisconsin

Search by objective public record fields.

Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index

Biomarkers to Detect Endocrine Therapy Resistance

Predicting Effective Therapy in Pancreatic Cancer

Regional Anesthesia Versus General Anesthesia on Circulating Tumor Cells (CTC)

Circulating Tumor Cells in Non-Small Cell Lung Carcinoma

Culture and Characterization of Circulating Tumor Cells (CTC) in Melanoma and Other Cancers

Circulating Tumor Cells (CTCs) as a Blood-based Tumor Marker in Patients With Small Cell Lung Cancer (SCLC)

Cancer Stem Cell Markers and Prognostic Markers in Circulating Tumor Cells

Virtual Colonoscopy (VC) for Primary Colorectal Screening

CTCs in Cervix Cancer

Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells

CTC Immune Checkpoint

Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma

Registry of CytoSorb Therapy in COVID-19 ICU Patients

OSCAR I STUDY - The ONCObind CTC Removal Study

Trastuzumab and Vinorelbine in Advanced Breast Cancer

The National CT Colonography Trial

Japanese National Computed Tomographic (CT) Colonography Trial

A Study for CTC Expression and cfDNA/RNA Assessment in Metastatic Breast Cancer Patients

Circulating Tumors Cells and Circulating Endothelial Cells in Renal Cell Carcinoma

A Pilot Surveillance Study to Monitor Natural Killer Cells and Circulating Tumor Cells in Women With Previously Treated Non-metastatic Triple Negative Breast Cancer and Women With Previously Treated Non-metastatic Breast Cancer With a Confirmed BRCA Mutation.

Plasma Circulating Tumor DNA Analyses in ER+ Metastatic Breast Cancer

ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials